Carvedilol: Difference between revisions
(edited dosage forms, strengths, routes of administration) |
Elcatracho (talk | contribs) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: Beta-blocker | *Type: [[Beta-blocker]] | ||
*Dosage Forms: extended-release capsule, tablet | *Dosage Forms: extended-release capsule, tablet | ||
*Dosage Strengths: capsule, extended release: 10mg, 20mg, 40mg, 80mg; tablet: 3.125mg, 6.25mg, 12.5mg, 25mg | *Dosage Strengths: capsule, extended release: 10mg, 20mg, 40mg, 80mg; tablet: 3.125mg, 6.25mg, 12.5mg, 25mg | ||
| Line 50: | Line 50: | ||
==See Also== | ==See Also== | ||
*[[Beta-blockers]] | *[[Beta-blockers]] | ||
*[[Beta-blocker toxicity]] | |||
*[[Antiarrhythmics]] | |||
*[[Antihypertensive medications]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] [[Category:Cardiology]] | ||
Latest revision as of 01:18, 7 March 2021
Administration
- Type: Beta-blocker
- Dosage Forms: extended-release capsule, tablet
- Dosage Strengths: capsule, extended release: 10mg, 20mg, 40mg, 80mg; tablet: 3.125mg, 6.25mg, 12.5mg, 25mg
- Routes of Administration: PO
- Common Trade Names: Coreg
Adult Dosing
- 3.125-50mg BID
Pediatric Dosing
Safety/efficacy not established
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: no adjustment
- Hepatic dosing: contraindicated in severe liver disease
Contraindications
- Allergy to class/drug
- Cardiogenic shock
- Asthma or other bronchospastic condition
- 2nd or 3rd degree AV block, severe bradycardia, sick sinus
- Severe hepatic impairment
Adverse Reactions
Serious
- AV block, bradyarrhythmia, hypotension
- SJS/TEN
- Aplastic anemia
- Asthma with status asthmaticus
- Intraoperative floppy iris syndrome (?!)
Common
- Bradyarrhythmia, hypotension
- Peripheral edema
- Weight gain, hyperglycemia
- Diarrhea
- Dizziness, fatigue
- Erectile dysfunction
Pharmacology
- Half-life: 7-10h
- Metabolism: Hepatic CYP2D6
- Excretion: Fecal/biliary
Mechanism of Action
- Nonselective beta-blocker with α-1 blocking activity